A wide range of insulins is now available with various durations of action that can help to improve glycemic control. A recent study from the Veterans Administration demonstrated improved glycemic control with lowered hemoglobin A 1c in patients with insulin-treated type 2 diabetes who performed SMBG ( 2 ). By measuring real-time glucose, informed patients can modify their diabetes management acutely or prospectively to sustain glucose in a narrow range near normal. Winter 1 University of Florida, Department of Pathology, Immunology and Laboratory Medicine, Box 100275, Gainesville, FL 32610-0275, Fax 35, E-mail In the daily management of type 1 diabetes, self-monitoring of blood glucose (SMBG) is the recommended glycemic monitor, or вЂњRosetta stoneвЂќ, that enables improved glycemic control ( 1 ). Clinical Chemistry American Association for Clinical Chemistry ДЄ Rosetta Stone for Insulin Treatment: Self-Monitoring of Blood Glucose William E. Novel insulins such as lyspro-insulin have a very rapid onset of action (15вЂ“30 min), peak effect (1вЂ“2 h), and limited overall duration of action (3вЂ“4 h), whereas glargine ( A -Gly-30 B a- l -Arg-30 B h- l -Arg-human) has no peak and a duration of action of 24 h The greatest therapeutic advances entail the use of recombinant DNA-engineered insulin analogs.

A Rosetta Stone for Insulin Treatment: Self-Monitoring of Blood Glucose A Rosetta Stone for Insulin Treatment: Self-Monitoring of Blood GlucoseДЄ Rosetta Stone for Insulin Treatment: Self-Monitoring of Blood Glucose William E.

Rosetta stone 3.4.5 fatal error 2120